Next Article in Journal
The First Complete Chloroplast Genome of Cordia monoica: Structure and Comparative Analysis
Previous Article in Journal
Positive Regulation of Splicing of Cellular and Viral mRNA by Intragenic RNA Elements That Activate the Stress Kinase PKR, an Antiviral Mechanism
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 14
Issue 5
10.3390/genes14050975
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hypoxia-Inducible Pathway Polymorphisms and Their Role in the Complications of Prematurity

by
Ewa Strauss
1,*,
Anna Gotz-Więckowska
2,
Alicja Sobaniec
3,
Anna Chmielarz-Czarnocińska
2,
Dawid Szpecht
3 and
Danuta Januszkiewicz-Lewandowska
4,5,*
1
Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland
2
Department of Ophthalmology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznan, Poland
3
Department of Neonatology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland
4
Department of Medical Diagnostics, Poznan University of Medical Sciences, Dobra Street 38a, 60-595 Poznan, Poland
5
Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Szpitalna 27/33, 60-572 Poznan, Poland
*
Authors to whom correspondence should be addressed.
Genes 2023, 14(5), 975; https://doi.org/10.3390/genes14050975
Submission received: 28 February 2023 / Revised: 18 April 2023 / Accepted: 24 April 2023 / Published: 26 April 2023
(This article belongs to the Section Molecular Genetics and Genomics)
Browse Figures
Review Reports Versions Notes

Abstract

:
Excessive oxidative stress resulting from hyperoxia or hypoxia is a recognized risk factor for diseases of prematurity. However, the role of the hypoxia-related pathway in the development of these diseases has not been well studied. Therefore, this study aimed to investigate the association between four functional single nucleotide polymorphisms (SNPs) in the hypoxia-related pathway, and the development of complications of prematurity in relation to perinatal hypoxia. A total of 334 newborns born before or on the 32nd week of gestation were included in the study. The SNPs studied were HIF1A rs11549465 and rs11549467, VEGFA rs2010963, and rs833061. The findings suggest that the HIF1A rs11549465T allele is an independent protective factor against necrotizing enterocolitis (NEC), but may increase the risk of diffuse white matter injury (DWMI) in newborns exposed to hypoxia at birth and long-term oxygen supplementation. In addition, the rs11549467A allele was found to be an independent protective factor against respiratory distress syndrome (RDS). No significant associations with VEGFA SNPs were observed. These findings indicate the potential involvement of the hypoxia-inducible pathway in the pathogenesis of complications of prematurity. Studies with larger sample sizes are needed to confirm these results and explore their clinical implications.

1. Introduction

Preterm birth is a significant cause of perinatal mortality and morbidity, with an estimated 15 million premature births occurring annually worldwide, accounting for 11% of all births [1,2]. In Poland, 6% of all births are premature. Preterm birth is the leading cause of death among children under the age of 5, responsible for 18% of all deaths in this age group and 35% of all deaths among newborns aged <28 days [3]. Premature newborns are highly susceptible to various diseases, including necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), respiratory distress syndrome (RDS), diffuse white matter injury (DWMI, previously referred to as periventricular leukomalacia), and retinopathy of prematurity (ROP) [4,5,6,7,8,9,10]. Oxidative stress, defined as an imbalance between increased reactive species and a lack of protective antioxidant capacity, has been identified as a key factor in the pathogenesis of these diseases [9].
The postnatal transition from a hypoxic intrauterine environment with 20–25 mmHg oxygen tension to an extrauterine normoxic environment of approximately 100 mmHg oxygen tension is an oxidative challenge for newborns [11,12]. Premature newborns are particularly vulnerable to oxidative damage due to deficiencies in antioxidant defenses, oxygen supplementation, immunodeficiency, and high levels of free iron [9]. Oxidative stress is especially detrimental to newborns with perinatal hypoxia-ischemia, which can result in multi-organ dysfunction and neurological deficits, leading to neonatal morbidity and mortality [13]. Pulmonary illnesses are a primary cause of postnatal hypoxia in premature infants [9,10].
Hypoxia-inducible factor-1 (HIF-1) is a crucial regulator of oxygen homeostasis, enabling adaptive responses to hypoxic environments [14]. HIF-1 functions as a heterodimer, comprising the HIF-1α and HIF-1β subunits [15]. In normoxic conditions, the activity of HIF-1 is regulated by the degradation of the HIF-1α subunit. This degradation is primarily mediated by the oxygen-dependent hydroxylation of two proline residues (Pro402 or Pro564, or both), which interact with the von Hippel–Lindau (VHL) tumor-suppressing protein. VHL recruits an E3 ubiquitin–protein ligase complex, which targets HIF-1α for proteasomal degradation [16,17]. However, under hypoxic conditions, HIF-1α is stabilized against degradation, which leads to the upregulation of numerous genes involved in various biological processes, including glycolysis, angiogenesis, and erythropoiesis [18]. Among them, the vascular endothelial growth factor gene (VEGFA) is a key activator of hypoxia-induced angiogenesis.
The HIF1A gene encodes HIF-1α and is located at chromosome 14q21-24. It consists of 15 exons and has over 450 missense variants listed in the Ensembl database. These variants are associated with various predictions of protein function, and two of them, rs11549465 (c.1744C>T, p.Pro582Ser) and rs11549467 (c.1762G>A, p.Ala588Thr), located in exon 12, have been extensively studied [19,20]. Both of these single nucleotide polymorphisms (SNPs) are situated within the oxygen-dependent degradation domain that stabilizes HIF-1α against degradation, and they exhibit higher transcriptional activity of HIF1A under either normoxic or hypoxic conditions [21,22]. Another synonymous variant, rs41492849 (c.1692C>T), was observed within the codon for Pro564 in the same exon, but it was extremely rare (<1%). Recently, Kuney developed a detailed profile of HIF1A variants and regulatory elements [23]. The VEGFA gene, located at chromosome 6p21.3 and consisting of eight exons exhibiting alternative splicing [24], has numerous sequence variants. However, only a few of them, located in the 5′ untranslated region or the promoter region, have been demonstrated to regulate VEGFA expression. For example, the rs2010963 (−634G>C) variant is associated with decreased basal promoter activity and reduced protein production, while the rs833061 (−1498C>T) variant has the opposite effect [25,26].
Recent research has identified that genetic variations in HIF1A are associated with over 40 different phenotypes and diseases, such as cancer, cardiovascular diseases, and metabolic disorders [20,27]. However, the potential role of HIF1A in the development of prematurity-related diseases has yet to be investigated. On the other hand, previous studies have suggested that VEGFA variants may be associated with female reproductive diseases [28,29,30], and some neonatal populations have shown potential links between VEGFA and the consequences of prematurity, although these have not been consistently replicated [31]. Thus, the main objective of our analysis is to comprehensively examine the associations between HIF1A SNPs (rs11549465 and rs11549467) and VEGFA SNPs (rs2010963 and rs833061) with the occurrence of NEC, BPD, IVH, RDS, DWMI, or ROP, taking into account the presence of hypoxia at birth. Our research hypothesis is that the genetically determined activity of HIF-1 and VEGF may modulate the risk of developing prematurity-related diseases in infants who have been exposed to perinatal hypoxia.

2. Materials and Methods

2.1. Study Population

This study included 334 Caucasian preterm infants who were born between 22 and less than 32 weeks of gestation (classified as very preterm and extremely preterm according to World Health Organization (WHO) criteria) [3], and who were hospitalized between 2009 and 2020 at the Gynecology and Obstetrics Clinical Hospital of Poznan University of Medical Sciences. We excluded neonates born from multiple pregnancies, those with chromosomal abnormalities or TORCH infections, and infants who did not receive antenatal steroid therapy.
We analyzed several clinical factors, including gestational age (weeks), birth weight (grams), sex, time of preterm rupture of the fetal bladder (days), mode of delivery (vaginal delivery vs. cesarean section), Apgar scores at 1 and 5 min, parameters related to oxygen therapy (such as use of surfactant, duration of mechanical ventilation (days), and total oxygen supplementation period), as well as blood transfusions. We also collected data on the presence of several diseases of prematurity, including RDS, IVH, BPD, NEC, ROP, DWMI, sepsis, and jaundice of prematurity. We diagnosed RDS, NEC, IVH, BPD, and NEC using criteria that have been described previously [32], and we diagnosed DWMI based on abnormal US or MRI results. In ROP, we distinguished a subgroup of infants with an advanced proliferative form of the disease. We determined the criteria for the diagnosis of extremely low gestational age (<28 weeks, ELGA), extremely low birth weight (<1000 g, ELBW), and intrauterine hypotrophy (fetal weight below the 10th percentile according to the percentile grids for the corresponding GA) based on WHO guidelines [3].
To determine the presence of hypoxia at birth, we assessed whether the newborn fulfilled at least two of the following criteria: acidosis (pH ≤ 7.20 in umbilical vein), Apgar score ≤6 at 5 min, and a fraction of inspired oxygen (FiO2) ≥0.4 needed to achieve oxygen saturation ≥86% at birth. We chose these criteria, which are less severe than those used to define neonates with birth asphyxia, according to Buonocore et al. [11] to evaluate all hypoxic infants, even those with mild hypoxia. Hypoxic infants were reanalyzed separately to verify whether stricter criteria of hypoxia, established by the American College of Obstetricians and Gynecologists (ACOG) to define newborns with birth asphyxia (pH < 7.15 in umbilical vein, Apgar score < 5 at 5 min), changed the results on the relationship between hypoxia at birth and the occurrence of diseases in preterm infants.

2.2. Genotyping

Genomic DNA was extracted from buccal swabs using the innuPREP DNA Kit (Analytik Jena AG, Jena, Germany) or from circulating blood lymphocytes using the QIAamp DNA Kit (Qiagen GmbH, Hilden, Germany), following the manufacturer’s instructions. Polymorphisms were determined using pre-designed TaqMan SNP genotyping assays (rs11549465: C__25473074_10, rs11549467: C__34492744_10, rs2010963: C___8311614_10, and rs833061: C___1647381_10, Thermo Fisher Scientific, Waltham, MA, USA) and the ABI 7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad, CA, USA).

2.3. Data Analysis

Genotype frequencies were assessed for Hardy–Weinberg equilibrium using the χ2 test available at URL http://ihg.gsf.de/cgi-bin/hw/hwa1.pl (accessed on 12 December 2022). Univariate analyses were used to compare the demographic parameters of the study groups. Quantitative parameters were compared using the t-test or Mann–Whitney U test, and qualitative parameters using the χ2 test or Fisher’s test. The Shapiro–Wilk test was used to test the normality of the distribution. Odds ratios (ORs) and 95% confidence intervals (95%CI) were calculated for quantitative parameters. Multivariate analysis was performed using logistic regression analysis. The Bonferroni correction was used for multiple comparisons (padjusted). Statistical analyses were carried out using Statistica v10.0 software and GraphPad Prism v6 software. Quanto software was used for power analysis. Differences were considered significant when p < 0.05.

3. Results

3.1. Known Risk Factors and Comorbidities

Table 1 presents detailed characteristics of the premature infants included in the study. The mean gestational age of the 334 enrolled infants was 27.6 ± 2.0 weeks, with a range between 22 and less than 32 weeks. The mean birth weight was 1114.2 ± 335.0 g, with a range of 432–2340 g. The prevalence of complications related to prematurity varied considerably, with rates ranging from 4.5% for death and 7.9% for DWMI to 23.4% for NEC, 23.4% for sepsis, 38.9% for BPD, 57.5% for IVH, 63.5% for ROP, 66.5% for RDS, and 83% for neonatal jaundice. Hypoxia at birth was found in 154 infants (46.1%), and it was associated with low gestational age and birth weight, low Apgar scores at 1 and 5 min, acidemia, high oxygen concentration in the respiratory mixture (FiO2 ≥ 0.4), treatment with surfactant, resuscitation, mechanical ventilation, and prolonged oxygen supply. Hypoxia at birth was also identified as a risk factor for several complications, including NEC, BPD, IVH, RDS, ROP, and DWMI, as well as death (Figure 1a).
Sixty six of the 154 hypoxic infants, which accounts for 42.9% of this subgroup, met the ACOG criteria for hypoxia. The frequencies of all studied comorbidities and death were similar in groups meeting both the broader and narrower criteria for birth hypoxia.
However, meeting the ACOG criteria was significantly associated only with BPD, IVH, RDS, ROP, and DWMI, but not NEC and death, as observed in the analyses based on the broader criteria of hypoxia (refer to Supplementary Table S1).

3.2. Frequency of HIF1A and VEGFA SNPs

Table 2 presents the distribution of the HIF1A and VEGFA genotypes in the entire study group. Genotyping of HIF1A revealed that the rs11549465 SNP occurred more frequently in the studied population than the rs11549467 variant, with observed frequencies of 0.076 for rs11549465T and 0.027 for rs11549467A. Genotyping of VEGFA showed a higher frequency of the rs833061 SNP than the rs2010963 variant, with observed frequencies of 0.284 for rs2010963C and 0.400 for rs833061T. The genotype distributions in the studied HIF1A SNPs did not deviate from the Hardy–Weinberg equilibrium. However, in the case of VEGFA, the distribution of the rs833061 genotypes showed an overabundance of heterozygotes (pHWE = 0.049).

3.3. HIF1A and VEGFA SNPs and Comorbidities

The results of the univariate analyses are shown in Figure 2 and Supplementary Tables S2–S4. Among the HIF1A and VEGFA variants studied, only the HIF1A polymorphisms were found to be associated with prematurity comorbidities. Protective effects against NEC and RDS were observed for the rs11549465T and rs11549467A alleles, respectively. The rs11549465T allele was found also to be a risk factor for IVH and proliferative ROP as well as DWMI, but only in infants exposed to hypoxia at birth (OR = 3.5 (95%CI [1.3–9.0], p = 0.015; padjusted = 0.03).
The relationship between the HIF1A genotype, hypoxia at birth, and the development of DWMI indicated a gene–environment interaction. Coexistence of carrying the rs11549465T allele and hypoxia resulted in a 5.2-fold increase in the risk of DWMI (95%CI: 1.7–16.1; p = 0.008; padjusted = 0.016), compared to the risk of this disease in infants with the rs11549465CC genotype who were not exposed to hypoxia at birth. The observed OR value indicates an amplification of the combined effect over the additive effect of individual factors.
Further evaluation of potential factors that could modify the observed effect or more precisely predict DWMI showed that the need for prolonged mechanical ventilation could be a prognostic indicator of this disease in the studied group of infants born prematurely. The cumulative effect of the HIF1A rs11549465T allele, hypoxia at birth, and prolonged oxygen supplementation increased the risk of DWMI by 7.4 times (p = 0.005, padjusted = 0.015, Figure 3). ROP, BPD and IVH were the diseases most frequently comorbid with DWMI (Figure 1B).

3.4. Multivariate Analysis

The multivariate statistical analysis considered the HIF1A genotype and all potential clinical risk factors that may affect the risk of developing diseases in preterm infants. This analysis confirmed that the HIF1A rs11549465T allele was an independent from age, body mass and sex, and a protective factor for NEC (OR = 0.19, 95%CI [0.07–0.54], p = 0.002; padjusted = 0.01), while the rs11549467A allele was a protective factor for RDS (OR = 0.24, 95%CI [0.09–0.68], p = 0.007; padjusted = 0.035; Supplemental Table S5). The co-occurrence of the HIF1A rs11549465T allele with hypoxia at birth, and prolonged oxygen supply, but not gestational age, birth weight and sex, were independent risk factors for DWMI. In the regression model adjusted for other confounders, the co-occurrence of the rs11549465T allele with hypoxia at birth was associated with a 4.0-fold increase in the risk of DWMI (95%CI [1.2–12.9], p = 0.020). In the analysis that included only significant risk factors, the risk of this disease related to coexistence of genotype and hypoxia was increased by 4.5 times (95%CI [1.4–14.1], p = 0.009, padjusted = 0.027). No independent association was found between the HIF1A genotype and the development of IVH and ROP upon multivariate analysis. Low gestational age and birth weight were important risk factors for this condition.

4. Discussion

Hypoxia is a trigger of oxidative stress and a significant factor contributing to the pathogenesis of prematurity-related diseases. However, it remains uncertain whether this relationship is causative. In our study, we examined the associations between HIF1A and VEGFA gene variants, which act as a proxy for exposure to increased hypoxia-inducible pathway activity and angiogenesis stimulation, and the occurrence of comorbidities (NEC, BPD, IVH, RDS, DWMI, and ROP) in newborns born on or before the 32nd week of gestation. Our findings suggest that the HIF1A rs11549465T allele is an independent protective factor against the occurrence of NEC, but it may also increase the risk of DWMI in newborns exposed to hypoxia at birth and long-term oxygen supplementation. Additionally, the rs11549467A allele was an independent protective factor against RDS. We confirmed the role of recognized risk factors such as gestational age, birth weight, and prolonged oxygen supply in the development of prematurity-related diseases. However, we found no associations between the VEGFA gene variants and these diseases.
The interrelationship between gestational age, birth weight, and neonatal morbidity is well documented. The incidence of severe respiratory problems and other morbidities decreases with increasing gestational age and birth weight. The prevalence of prematurity-related diseases reported in the literature varies between European countries and the USA. For example, the incidence of NEC ranges from 2–13%, ROP from 23–52%, BPD from 10–89%, IVH from 31–36%, RDS from 7–50%, and DWMI from 8–20% [1,10]. In our study population, which consisted of infants born very preterm (58%) and extremely preterm (42%), RDS was the most frequently observed diagnosis (66.5%), followed by ROP (63.5%), IVH (57.5%), BPD (38.9%), NEC (23.4%), and DWMI (8%). These findings confirm that RDS is the most common diagnosis in infants born prematurely.
The pathogenesis of all these diseases is linked to organ immaturity, insufficient immune and antioxidant systems, environmental factors such as infections and changes in oxygen concentrations, and genetic risk factors [5,6,7,33,34,35,36,37]. Hypoxic-ischemic injury at birth affects survival and is thought to be critical for all these diseases, as observed in this study. Almost half of the newborns showed symptoms of hypoxia at birth, which were associated with death, a 3.5- to 5-fold higher risk of BPD, IVH, and ROP, or approximately 2-fold higher risk of DWMI, NEC, and RDS. The ACOG criteria for hypoxia were met by 19.8% of the studied infants, which is consistent with previous studies by Buonocore et al. [11], who found it in 20.4% of premature infants born between 26–36 weeks of gestation. Based on an analysis of the concentration of blood biomarkers of oxidative stress, including plasma levels of hypoxanthine, total hydroperoxide, and advanced oxidation protein products, the authors found that preterm newborns exposed to hypoxia are at an increased risk of oxidative stress in the first week of life. The results were consistent regardless of whether the broader or stricter (ACOG) criteria were used to identify infants at risk for hypoxia at birth. In our study, the prevalence of comorbidities was similar in the groups of hypoxic neonates selected using different criteria, indicating that the broader criteria proposed by Buonocore and colleagues were more effective in excluding cases exposed to hypoxia at birth from the control group. This result indicates a possible underestimation of the role of hypoxia at birth on the development of comorbidities associated with prematurity.
According to the literature, the strongest effect of hypoxia at birth can be expected in the case of DWMI, since the central nervous system (CNS) is highly sensitive to oxygen deficiency. During gestation, the development of the CNS is stimulated by exposure to physiological hypoxia, under which HIF-1α is stabilized and plays a crucial role in regulating neural development [38]. Premature delivery disrupts this process and can lead to the development of DWMI. Immature cerebrovascular development, birth asphyxia, and high concentrations of free ions leading to excessive free radical formation and other toxic compounds, such as peroxynitrite, are the most significant causes of injury to the (fetal) brain [13,39,40]. This study also found that prolonged oxygen supply is a subsequent predictor of this condition. It is unclear whether this relationship is causal, but previous studies also report a specific association between respiratory failure and brain injury. Therefore, continuously monitoring the respiratory rate in the neonatal intensive care unit is postulated to be useful in predicting CNS pathology [41]. A novelty with respect to previous studies is the indication of the importance of the HIF1A genotype in determining susceptibility to birth hypoxia-related DWMI occurrence.
The relationship between HIF1A alleles and the occurrence of NEC and RDS appears to involve a complex pathomechanism that encompasses various factors associated with fetal development and the activation of the inflammatory cascade by HIF-1α. Animal models of NEC suggest that altered vascular development and tone, which are components of intestinal immaturity, coupled with early exposure to cold stress and a non-milk diet, contribute to the disease [8]. HIF1A SNPs may affect fetal intestinal development and modulate the in utero environment by activating proinflammatory cytokines. Previous studies have linked higher concentrations of HIF-1α in amniotic fluid with a shorter amniocentesis-to-delivery interval and increased levels of IL1α, IL6, and TNFα, indicating the possibility of HIF-1α contributing to the inflammatory cascade in complicated pregnancies [42]. However, the source of HIF-1α (the mother or the fetus) remains unclear. Despite this, infection or inflammation can significantly contribute to early spontaneous preterm birth, and this adverse intrauterine environment plays a crucial role in impairing organ development, particularly the pulmonary maturation process. High levels of cytokines in the amniotic fluid lead to direct exposure of the fetal lung to proinflammatory factors, resulting in the arrest of lung development and an increased risk of respiratory diseases after birth, including RDS [43].
The opposite role of high HIF-1 activity in various diseases and conditions is a common observation. Genetically determined high activity of HIF-1, which has proangiogenic effects, benefits adaptation to hypoxia in high altitudes, ischemia related to cardiovascular disease, premature coronary artery disease, and pregnancy complicated by preeclampsia [44,45,46,47]. Under hypoxic conditions, HIF-1 activates the transcription of numerous target genes that regulate various processes, including erythropoiesis, angiogenesis, and glucose metabolism. However, exposure to elevated oxygen concentrations can cause early inactivation of these pathways in preterm infants. Additionally, exogenous oxygen administration may suppress HIF-1 activity, leading to clinically significant anemia. It is also believed that the in utero hypoxic environment protects the integrity of the intestinal epithelium, and oxygen exposure during preterm labor may increase the risk of necrotizing enterocolitis (NEC) in these infants. The HIF-1α subunit in normoxia is degraded through the ubiquitin-proteasome-prolyl hydroxylase domain (PHD) pathway; therefore, developing PHD inhibitors may be a potential strategy to pharmacologically stabilize HIF-1 to allow normal development [48,49].
On the other hand, high HIF-1 activity may be unfavorable in pathological angiogenesis, accompanying the development of solid tumors and inflammatory diseases, which may also apply to ROP. Experimental studies have demonstrated that pharmacological HIF-1 inhibition can prevent retinal neovascularization, leading to improved visual function in murine oxygen-induced ROP [50]. Anti-VEGF drugs are currently used in clinical practice to treat several types of cancers and ROP. In this study, no associations were found between VEGFA SNPs and the outcomes of interest. However, recent studies suggest that SNPs in this gene other than the ones examined in this analysis may have a greater impact on gene expression and protein levels [51]. Therefore, further research on this gene seems advisable.
One limitation of this study is its relatively small sample size for genetic research into DWMI. Post hoc power analysis, however, showed a statistical power of nearly 80% for the association analyses between HIF1A SNPs and RDS and NEC. Additionally, the results obtained met the criteria of the Bonferroni correction for multiple comparisons. The other limitation is the lack of data to assess the impact of the SNPs studied on the outcome of ROP treatment and the advancement of IVH. The latter may have contributed to the overrepresentation of IVH in the study population (57.5%) as well as the underestimation of the effect of the HIF1A genotype on IVH. As shown in our previous study, in a smaller group of cases in which any stage of IVH (grade I–IV in ultrasound classification) was present in 44% of infants, a stronger influence of genetic factors can be found for severe IVH (grade II–IV), occurring in approximately 60% of cases. Stage I (42% of IVH cases), defined as unilateral or bilateral reproductive matrix haemorrhage, can be excluded from association studies as a condition with low genetic impact [52]. A significant advantage in terms of the research conducted and the results obtained is that the study population is strictly defined and ethnically homogeneous.

5. Conclusions

In conclusion, our findings suggest a potential role of the hypoxia-inducible pathway in the pathogenesis of preterm complications, specifically DWMI, NEC, and RDS. Hypoxia at birth and prolonged oxygen supply were independent predictors of DWMI. Further studies with larger sample sizes are needed to confirm these findings and explore their clinical implications. Additionally, exploring the impact of these genetic variations on treatment outcomes may provide valuable insights for personalized management strategies for preterm infants. Studies focusing on the role of local or systemic pharmacological inhibition of HIF-1 and VEGF or, on the other hand, targeting the development of pharmacotherapy for HIF-1 stabilization and antioxidant supplementation, may be suggested based on a risk assessment that includes HIF1A’s genotype and clinical risk factor profile. Since even mild hypoxia has been shown to be significantly associated with complications of prematurity, more careful monitoring of oxygen supplementation could be recommended until new effective pharmacotherapy is found. Understanding the implications of our observations is of great importance for improving the care of premature babies in intensive care units.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes14050975/s1, Table S1: Reanalysis of a group of infants who meet stricter ACOG criteria for hypoxia. Table S2: Relationship between HIF1A SNPs and the presence of comorbidities of prematurity or hypoxia at birth in premature infants. Table S3: Relationship between HIF1A SNPs and the presence of comorbidities of prematurity in relation to hypoxia at birth; Table S4: Relationship between VEGFA SNPs and the presence of comorbidities of prematurity or hypoxia at birth in premature infants; Table S5: Multivariate statistical analysis to assess the independent effect of HIF1A genotype on the development of comorbidities of prematurity.

Author Contributions

Conceptualization, methodology E.S., A.G.-W. and D.J.-L.; investigation E.S., A.G.-W., A.S., A.C.-C. and D.S. Funding acquisition E.S., A.G.-W., A.C.-C. and D.J.-L.; writing—original draft preparation E.S. and D.J.-L.; writing—review and editing A.G.-W., A.S., A.C.-C. and D.S.; data curation A.G.-W., A.S., A.C.-C., D.S. and E.S.; visualization E.S.; supervision E.S. All authors have read and agreed to the published version of the manuscript.

Funding

The work has been supported by the Scientific Research Committee in Poland under grant no. 2 P05E 098 30 (A.G.-W. and E.S.) and the Poznan University of Medical Sciences research grant for young employees (up to 35 years of age) and participants of four-year doctoral studies in 2018, no. 502-14-11121500-41229 (A.C.-C. and E.S.).

Institutional Review Board Statement

All procedures carried out on human participants in this study were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments (or comparable ethical standards). The study was approved by the Bioethics Committee of Poznan University of Medical Sciences (no. 1140/05 and 1117/18).

Informed Consent Statement

Informed consent was obtained from all parents of subjects involved in the study.

Data Availability Statement

All data generated or analyzed during this study are included in the published article (and its Supplementary Information files).

Acknowledgments

We would like to thank the students Aleksandra Landowska, Malgorzata Czarnecka, and Weronika Starzak for their significant contribution to DNA isolation, preparation of DNA sample banks and/or genotyping (under supervision of ES).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO. 2022. Available online: https://www.who.int/en/news-room/fact-sheets/detail/preterm-birth (accessed on 12 December 2022).
  2. Walani, S.R. Global burden of preterm birth. Int. J. Gynaecol. Obstet. 2020, 150, 31–33. [Google Scholar] [CrossRef] [PubMed]
  3. WHO. Recommendations for Care of the Preterm or Low-Birth-Weight Infant; World Health Organization: Geneva, Switzerland, 2022.
  4. Papile, L.A.; Burstein, J.; Burstein, R.; Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1500 gm. J. Pediatr. 1978, 92, 529–534. [Google Scholar] [CrossRef] [PubMed]
  5. Ballabh, P. Pathogenesis and prevention of intraventricular hemorrhage. Clin. Perinatol. 2014, 41, 47–67. [Google Scholar] [CrossRef] [PubMed]
  6. Ehrenkranz, R.A.; Walsh, M.C.; Vohr, B.R.; Jobe, A.H.; Wright, L.L.; Fanaroff, A.A.; Wrage, L.A.; Poole, K. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005, 116, 1353–1360. [Google Scholar] [CrossRef] [PubMed]
  7. Hartnett, M.E. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology 2015, 122, 200–210. [Google Scholar] [CrossRef]
  8. Tanner, S.M.; Berryhill, T.F.; Ellenburg, J.L.; Jilling, T.; Cleveland, D.S.; Lorenz, R.G.; Martin, C.A. Pathogenesis of necrotizing enterocolitis: Modeling the innate immune response. Am. J. Pathol. 2015, 185, 4–16. [Google Scholar] [CrossRef]
  9. Ozsurekci, Y.; Aykac, K. Oxidative Stress Related Diseases in Newborns. Oxidative Med. Cell. Longev. 2016, 2016, 2768365. [Google Scholar] [CrossRef]
  10. Lembo, C.; Buonocore, G.; Perrone, S. Oxidative Stress in Preterm Newborns. Antioxidants 2021, 10, 1672. [Google Scholar] [CrossRef]
  11. Buonocore, G.; Perrone, S.; Longini, M.; Vezzosi, P.; Marzocchi, B.; Paffetti, P.; Bracci, R. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr. Res. 2002, 52, 46–49. [Google Scholar] [CrossRef]
  12. Buonocore, G.; Perrone, S.; Longini, M.; Terzuoli, L.; Bracci, R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr. Res. 2000, 47, 221–224. [Google Scholar] [CrossRef]
  13. Frajewicki, A.; Laštůvka, Z.; Borbélyová, V.; Khan, S.; Jandová, K.; Janišová, K.; Otáhal, J.; Mysliveček, J.; Riljak, V. Perinatal hypoxic-ischemic damage: Review of the current treatment possibilities. Physiol. Res. 2020, 69 (Suppl. S3), S379–S401. [Google Scholar] [CrossRef] [PubMed]
  14. Semenza, G.L. Oxygen homeostasis. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2, 336–361. [Google Scholar] [CrossRef] [PubMed]
  15. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510–5514. [Google Scholar] [CrossRef] [PubMed]
  16. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001, 292, 464–468. [Google Scholar] [CrossRef]
  17. Kallio, P.J.; Wilson, W.J.; O’Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274, 6519–6525. [Google Scholar] [CrossRef]
  18. Semenza, G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148, 399–408. [Google Scholar] [CrossRef]
  19. Hon, W.C.; Wilson, M.I.; Harlos, K.; Claridge, T.D.; Schofield, C.J.; Pugh, C.W.; Maxwell, P.H.; Ratcliffe, P.J.; Stuart, D.I.; Jones, E.Y. Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 2002, 417, 975–978. [Google Scholar] [CrossRef]
  20. Gladek, I.; Ferdin, J.; Horvat, S.; Calin, G.A.; Kunej, T. HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies. Genes Chromosomes Cancer 2017, 56, 439–452. [Google Scholar] [CrossRef]
  21. Tanimoto, K.; Yoshiga, K.; Eguchi, H.; Kaneyasu, M.; Ukon, K.; Kumazaki, T.; Oue, N.; Yasui, W.; Imai, K.; Nakachi, K.; et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003, 24, 1779–1783. [Google Scholar] [CrossRef]
  22. Fu, X.S.; Choi, E.; Bubley, G.J.; Balk, S.P. Identification of hypoxia-inducible factor-1α (HIF-1α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005, 63, 215–221. [Google Scholar] [CrossRef]
  23. Kunej, T. Integrative Map of HIF1A Regulatory Elements and Variations. Genes 2021, 12, 1526. [Google Scholar] [CrossRef]
  24. Wei, M.H.; Popescu, N.C.; Lerman, M.I.; Merrill, M.J.; Zimonjic, D.B. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum. Genet. 1996, 97, 794–797. [Google Scholar] [CrossRef] [PubMed]
  25. Stevens, A.; Soden, J.; Brenchley, P.E.; Ralph, S.; Ray, D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003, 63, 812–816. [Google Scholar] [PubMed]
  26. Koukourakis, M.I.; Papazoglou, D.; Giatromanolaki, A.; Bougioukas, G.; Maltezos, E.; Sivridis, E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004, 46, 293–298. [Google Scholar] [CrossRef] [PubMed]
  27. Ren, H.; Luo, J.Q.; Gao, Y.C.; Chen, M.Y.; Chen, X.P.; Zhou, H.H.; Jiang, Y.; Zhang, W. Genetic association of hypoxia inducible factor 1-α (HIF1A) Pro582Ser polymorphism with risk of diabetes and diabetic complications. Aging 2020, 12, 12783–12798. [Google Scholar] [CrossRef]
  28. Sajjadi, M.S.; Ghandil, P.; Shahbazian, N.; Saberi, A. Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage. J. Obstet. Gynaecol. Res. 2020, 46, 369–375. [Google Scholar] [CrossRef]
  29. Wang, X.; Sun, T.; Chen, G.; Gao, H. Association between Vascular Endothelial Growth Factor Gene Polymorphisms and Pre-Eclampsia Susceptibility: An Updated Meta-Analysis. Immunol. Investig. 2020, 49, 120–133. [Google Scholar] [CrossRef]
  30. Langmia, I.M.; Apalasamy, Y.D.; Omar, S.Z.; Mohamed, Z. Association of VEGFA gene polymorphisms and VEGFA plasma levels with spontaneous preterm birth. Pharm. Genom. 2015, 25, 199–204. [Google Scholar] [CrossRef]
  31. Mahlman, M.; Huusko, J.M.; Karjalainen, M.K.; Kaukola, T.; Marttila, R.; Ojaniemi, M.; Haataja, R.; Lavoie, P.M.; Rämet, M.; Hallman, M. Genes Encoding Vascular Endothelial Growth Factor A (VEGF-A) and VEGF Receptor 2 (VEGFR-2) and Risk for Bronchopulmonary Dysplasia. Neonatology 2015, 108, 53–59. [Google Scholar] [CrossRef]
  32. Kosik, K.; Szpecht, D.; Al-Saad, S.R.; Karbowski, L.M.; Kurzawińska, G.; Szymankiewicz, M.; Drews, K.; Wolski, H.; Seremak-Mrozikiewicz, A. Single nucleotide vitamin D receptor polymorphisms (FokI, BsmI, ApaI, and TaqI) in the pathogenesis of prematurity complications. Sci. Rep. 2020, 10, 21098. [Google Scholar] [CrossRef]
  33. Holme, N.; Chetcuti, P. The pathophysiology of respiratory distress syndrome in neonates. Paediatr. Child Health 2012, 22, 507–512. [Google Scholar] [CrossRef]
  34. Thekkeveedu, K.; Guaman, M.C.; Shivanna, B. Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology. Respir. Med. 2017, 132, 170–177. [Google Scholar] [CrossRef] [PubMed]
  35. Dani, C.; Corsini, I.; Bertini, G.; Pratesi, S.; Barp, J.; Rubaltelli, F.F. Effect of multiple INSURE procedures in extremely preterm infants. J. Matern. Fetal Neonatal Med. 2011, 24, 1427–1431. [Google Scholar] [CrossRef]
  36. Hirsch, K.; Taglauer, E.; Seedorf, G.; Callahan, C.; Mandell, E.; White, C.W.; Kourembanas, S.; Abman, S.H. Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental Bronchopulmonary Dysplasia. Am. J. Respir. Crit. Care Med. 2020, 202, 1146–1158. [Google Scholar] [CrossRef] [PubMed]
  37. Pan, X.; Gong, D.; Nguyen, D.N.; Zhang, X.; Hu, Q.; Lu, H.; Fredholm, M.; Sangild, P.T.; Gao, F. Early microbial colonization affects DNA methylation of genes related to intestinal immunity and metabolism in preterm pigs. DNA Res. 2018, 25, 287–296. [Google Scholar] [CrossRef]
  38. Zhang, S.; Wang, Y.; Xu, J.; Kim, B.; Deng, W.; Guo, F. HIFα Regulates Developmental Myelination Independent of Autocrine Wnt Signaling. J. Neurosci. 2021, 41, 251–268. [Google Scholar] [CrossRef]
  39. Zaghloul, N.; Patel, H.; Ahmed, M.N. A model of Periventricular Leukomalacia (PVL) in neonate mice with histopathological and neurodevelopmental outcomes mimicking human PVL in neonates. PLoS ONE 2017, 12, e0175438. [Google Scholar] [CrossRef]
  40. Bel, F.V.; Groenendaal, F. Birth asphyxia-induced brain damage: The long road to optimal reduction and prevention! Pediatr. Med. 2020, 3, 3. [Google Scholar]
  41. Kumar, N.; Akangire, G.; Sullivan, B.; Fairchild, K.; Sampath, V. Continuous vital sign analysis for predicting and preventing neonatal diseases in the twenty-first century: Big data to the forefront. Pediatr. Res. 2020, 87, 210–220. [Google Scholar] [CrossRef]
  42. Song, J.E.; Park, S.J.; Lee, K.Y.; Lee, W.J. Amniotic fluid HIF1α and exosomal HIF1α in cervical insufficiency patients with physical examination-indicated cerclage. J. Matern. Fetal Neonatal Med. 2019, 32, 2287–2294. [Google Scholar] [CrossRef]
  43. Adams Waldorf, K.M.; McAdams, R.M. Influence of infection during pregnancy on fetal development. Reproduction 2013, 146, R151–R162. [Google Scholar] [CrossRef] [PubMed]
  44. Liu, K.X.; Sun, X.C.; Wang, S.W.; Hu, B. Association of polymorphisms of 1772 (C-->T) and 1790 (G-->A) in HIF1A gene with hypoxia adaptation in high altitude in Sherpas. Chin. J. Med. Genet. 2007, 24, 230–232. [Google Scholar]
  45. Droma, Y.; Ota, M.; Hanaoka, M.; Katsuyama, Y.; Basnyat, B.; Neupane, P.; Arjyal, A.; Pandit, A.; Sharma, D.; Ito, M.; et al. Two hypoxia sensor genes and their association with symptoms of acute mountain sickness in Sherpas. Aviat. Space Environ. Med. 2008, 79, 1056–1060. [Google Scholar] [CrossRef] [PubMed]
  46. López-Reyes, A.; Rodríguez-Pérez, J.M.; Fernández-Torres, J.; Martínez-Rodríguez, N.; Pérez-Hernández, N.; Fuentes-Gómez, A.J.; Aguilar-González, C.A.; Alvarez-León, E.; Posadas-Romero, C.; Villarreal-Molina, T.; et al. The HIF1A rs2057482 polymorphism is associated with risk of developing premature coronary artery disease and with some metabolic and cardiovascular risk factors. The Genetics of Atherosclerotic Disease (GEA) Mexican Study. Exp. Mol. Pathol. 2014, 96, 405–410. [Google Scholar] [CrossRef]
  47. Andraweera, P.H.; Dekker, G.A.; Thompson, S.D.; Dissanayake, V.H.; Jayasekara, R.W.; Roberts, C.T. Hypoxia-inducible factor-1α gene polymorphisms in early and late onset preeclampsia in Sinhalese women. Placenta 2014, 35, 491–495. [Google Scholar] [CrossRef] [PubMed]
  48. Park, A.M.; Sanders, T.A.; Maltepe, E. Hypoxia-inducible factor (HIF) and HIF-stabilizing agents in neonatal care. Semin. Fetal Neonatal Med. 2010, 15, 196–202. [Google Scholar] [CrossRef]
  49. Hoppe, G.; Yoon, S.; Gopalan, B.; Savage, A.R.; Brown, R.; Case, K.; Vasanji, A.; Chan, E.R.; Silver, R.B.; Sears, J.E. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. Proc. Natl. Acad. Sci. USA 2016, 113, E2516–E2525. [Google Scholar] [CrossRef]
  50. Miwa, Y.; Hoshino, Y.; Shoda, C.; Jiang, X.; Tsubota, K.; Kurihara, T. Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model. Neurochem. Int. 2019, 128, 21–31. [Google Scholar] [CrossRef]
  51. Al-Habboubi, H.H.; Sater, M.S.; Almawi, A.W.; Al-Khateeb, G.M.; Almawi, W.Y. Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population. Eur. Cytokine Netw. 2011, 22, 154–158. [Google Scholar] [CrossRef]
  52. Kosik, K.; Szpecht, D.; Karbowski, Ł.; Al-Saad, S.R.; Chmielarz-Czarnocińska, A.; Minta, M.; Sowińska, A.; Strauss, E. Hemangioma-related gene polymorphisms in the pathogenesis of intraventricular hemorrhage in preterm infants. Child’s Nerv. Syst. 2023. [Google Scholar] [CrossRef]
Genes 14 00975 g001 550
Figure 1. Summarized results of univariate analyses of (a) associations between hypoxia at birth and the occurrence of neonatal comorbidities, and (b) between comorbidities and presence of DWMI. Open triangles indicate non-hypoxic conditions, and solid triangles indicate hypoxic conditions.
Figure 1. Summarized results of univariate analyses of (a) associations between hypoxia at birth and the occurrence of neonatal comorbidities, and (b) between comorbidities and presence of DWMI. Open triangles indicate non-hypoxic conditions, and solid triangles indicate hypoxic conditions.
Genes 14 00975 g001
Genes 14 00975 g002 550
Figure 2. Summarized results of univariate analyses of associations between HIF1A (a,b) and VEGFA (c,d) SNPs and comorbidities and the presence of hypoxia at birth. Open triangles indicate non-hypoxic conditions, and solid triangles indicate hypoxic conditions.
Figure 2. Summarized results of univariate analyses of associations between HIF1A (a,b) and VEGFA (c,d) SNPs and comorbidities and the presence of hypoxia at birth. Open triangles indicate non-hypoxic conditions, and solid triangles indicate hypoxic conditions.
Genes 14 00975 g002
Genes 14 00975 g003 550
Figure 3. Cumulative effect of hypoxia at birth, prolonged oxygen supplementation and HIF1A genotype on the development of diffuse white matter injury (DWMI). The lower arm of the graph indicates that the HIF1A rs11549465T allele is not linked to either hypoxia at birth alone (p = 0.535) or in combination with oxygen supply over 5 weeks (p = 0.752). Only the cumulative effect of the HIF1A rs11549465T allele, hypoxia at birth, and prolonged oxygen supplementation increased the risk of DWMI by more than 7-fold (p = 0.005).
Figure 3. Cumulative effect of hypoxia at birth, prolonged oxygen supplementation and HIF1A genotype on the development of diffuse white matter injury (DWMI). The lower arm of the graph indicates that the HIF1A rs11549465T allele is not linked to either hypoxia at birth alone (p = 0.535) or in combination with oxygen supply over 5 weeks (p = 0.752). Only the cumulative effect of the HIF1A rs11549465T allele, hypoxia at birth, and prolonged oxygen supplementation increased the risk of DWMI by more than 7-fold (p = 0.005).
Genes 14 00975 g003
Table
Table 1. Demographic and clinical features of the studied group of premature infants.
Table 1. Demographic and clinical features of the studied group of premature infants.
ParameterPremature Infants
N = 334		Non-Hypoxic
N = 180		Hypoxic
N = 154		p
Gestational age [wk.]M (SD)27.6 (2.0)28.3 (1.8)26.9 (2.0)<0.0001
Range22.0–31.923.0–31.922.0–31.9
Body weight [g]M (SD)1114.2 (335.0)1236.4 (323.2)971.4 (289.7)<0.0001
Range432–2340570–2340432–1900
Intrauterine hypotrophy, n (%)22 (6.6)10 (5.6)12 (7.8)0.411
Male sex, n (%)186 (55.7)101 (56.1)85 (55.2)0.866
Risk factors at birth
 Ruptured fetal bladder, n (%)95 (28.4)58 (32.6)37 (24.0)0.085
 Ruptured fetal bladder, [d], M (SD)3.2 (9.3)3.6 (9.4)2.7 (9.2)0.394
 Delivery by caesarean section, n (%)179 (53.6)93 (51.7)86 (55.8)0.445
 Apgar 1, Me (Q1, Q3)5 (2, 7)6 (5, 8)2 (1, 5)<0.0001
 Apgar 5, Me (Q1, Q3)7 (6, 8)8 (7, 9)6 (5, 7)<0.0001
 Apgar 5 ≤ 6, n (%)120 (35.9)8 (4.4)112 (72.7)<0.0001
 Acidemia, n (%)94 (28.1)11 (6.1)83 (53.9)<0.0001
 FiO2 ≥ 0.4, n (%)227 (68.0)80 (46.1)147 (95.5)<0.0001
 Hypoxia at birth, n (%)154 (46.1)0 (0.00)154 (100.0)NA
Parameters related to respiratory failure
 Surfactant treatment, n (%)156 (46.7)59 (32.8)97 (63.0)<0.0001
 Resuscitation, n (%)277 (82.9)136 (75,5)141 (91,5)<0.0001
 Mechanical ventilation, n (%)229 (68.6)115 (53.0)114 (97.44)<0.0001
 Mechanical ventilation period [d], M (SD)22.3 (24.5)16.8 (22.9)28.8 (24.8)<0.0001
 Oxygen supply period [d], M (SD)33.2 (34.7)24.7 (30.3)43.6 (34.8)<0.0001
 Oxygen supply >5 weeks, n (%)141 (42.2)53 (29.4)88 (57.1)<0.0001
 Blood transfusions, n (%)4.1 (3.4)3.2 (3.6)4.8 (3.1)0.0005
Complications of prematurity, n (%)
 NEC78 (23.4)30 (16.7)48 (31.2)0.002
 BPD130 (38.9)40 (22.2)90 (58.4)<0.0001
 IVH192 (57.5)79 (43.9)113 (73.4)<0.0001
 RDS220 (66.5)107 (59.4)113 (73.4)0.007
 ROP212 (63.5)88 (47.9)124 (80.5)<0.0001
 DWMI26 (7.9)9 (5.0)17 (11.0)0.040
 Sepsis78 (23.4)35 (19.6)43 (27.9)0.068
 Neonatal jaundice278 (83.2)147 (81.7)130 (84.4)0.506
 Death5 (4.5)0 (0.0)5 (3.2)0.019
Abbreviations and symbols: BPD, bronchopulmonary dysplasia; DWMI, diffuse white matter injury; FiO2, fraction of inspired oxygen; IVH, intraventricular hemorrhage; M (SD), mean (standard deviation); Me (Q1; Q3), median (interquartile range); NEC, necrotizing enterocolitis; n (%), number (percentage); RDS, respiratory distress syndrome; ROP, retinopathy of prematurity, The presence of hypoxia at birth was recognized if newborn fulfilled at least two of the following criteria: acidemia (pH ≤ 7.20 in umbilical vein), Apgar score ≤6 at 5 min, and a fraction of inspired oxygen (FiO2) ≥0.4 needed to achieve oxygen saturation ≥86% at birth.
Table
Table 2. The distribution of the HIF1A and VEGFA genotypes in the whole group of infants.
Table 2. The distribution of the HIF1A and VEGFA genotypes in the whole group of infants.
HIF1A
Genotype, n (%)		Premature Infants
N = 334		VEGFA
Genotype, n (%)		Premature Infants
N = 334
rs11549465 rs2010963
CC285 (85.3)GG164 (49.1)
CT47 (14.1)GC150 (44.9)
TT2 (0.6)CC20 (5.9)
T allele frequency0.076C allele frequency0.284
pHWE0.967pHWE0.059
rs11549467 rs833061
GG316 (94.6)CC129 (38.6)
GA18 (5.4)CT143 (42.8)
AA0 (0.0)TT62 (18.6)
A allele frequency0.027T allele frequency0.400
pHWE0.613pHWE0.049
Abbreviations and symbols: pHWE, significance level for deviation from Hardy–Weinberg equilibrium.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Strauss, E.; Gotz-Więckowska, A.; Sobaniec, A.; Chmielarz-Czarnocińska, A.; Szpecht, D.; Januszkiewicz-Lewandowska, D. Hypoxia-Inducible Pathway Polymorphisms and Their Role in the Complications of Prematurity. Genes 2023, 14, 975. https://doi.org/10.3390/genes14050975

AMA Style

Strauss E, Gotz-Więckowska A, Sobaniec A, Chmielarz-Czarnocińska A, Szpecht D, Januszkiewicz-Lewandowska D. Hypoxia-Inducible Pathway Polymorphisms and Their Role in the Complications of Prematurity. Genes. 2023; 14(5):975. https://doi.org/10.3390/genes14050975

Chicago/Turabian Style

Strauss, Ewa, Anna Gotz-Więckowska, Alicja Sobaniec, Anna Chmielarz-Czarnocińska, Dawid Szpecht, and Danuta Januszkiewicz-Lewandowska. 2023. "Hypoxia-Inducible Pathway Polymorphisms and Their Role in the Complications of Prematurity" Genes 14, no. 5: 975. https://doi.org/10.3390/genes14050975

APA Style

Strauss, E., Gotz-Więckowska, A., Sobaniec, A., Chmielarz-Czarnocińska, A., Szpecht, D., & Januszkiewicz-Lewandowska, D. (2023). Hypoxia-Inducible Pathway Polymorphisms and Their Role in the Complications of Prematurity. Genes, 14(5), 975. https://doi.org/10.3390/genes14050975

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop